Edition:
United States

Aurinia Pharmaceuticals Inc (AUP.TO)

AUP.TO on Toronto Stock Exchange

8.05CAD
20 Jun 2018
Change (% chg)

$0.09 (+1.13%)
Prev Close
$7.96
Open
$7.93
Day's High
$8.16
Day's Low
$7.93
Volume
36,399
Avg. Vol
39,117
52-wk High
$9.75
52-wk Low
$5.68

Chart for

About

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead... (more)

Overall

Beta: 3.74
Market Cap(Mil.): $657.55
Shares Outstanding(Mil.): 84.20
Dividend: --
Yield (%): --

Financials

  AUP.TO Industry Sector
P/E (TTM): -- 235.76 33.88
EPS (TTM): -0.54 -- --
ROI: -17.95 -5.45 13.21
ROE: -21.12 -6.94 15.18

BRIEF-Aurinia Reports Qtrly Loss Per Share $0.18

* AURINIA REPORTS FIRST QUARTER FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

May 10 2018

BRIEF-Aurinia Pharmaceuticals Reports Qtrly Loss Per Share ‍of $0.04​

* AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Mar 15 2018

BRIEF-Aurinia Pharmaceuticals Files For Mixed Shelf Of Up To $250 Mln

* AURINIA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION – SEC FILING Source text: [http://bit.ly/2CTvkK1] Further company coverage:

Jan 04 2018

Earnings vs. Estimates